麻子仁丸加减方治疗阿片类药物引起便秘的临床疗效观察

《麻子仁丸加减方治疗阿片类药物引起便秘的临床疗效观察》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、提要目的：阿片类药物是中、重度癌痛首选止痛药物，但便秘是伴随用药始终的主要副作用之一。本研究观察了麻子仁丸加减方治疗癌痛患者应用阿片类药物引起便秘的临床疗效。方法：选择66例符合纳入标准的肿瘤患者（经辨证属胃肠燥热，脾气亏虚者），按编号奇偶随机分为对照组（33例，口服乳果糖口服液）和观察组（33例，口服麻子仁丸加减方），观察比较两组患者治疗前后首次排便时间、排便间隔时间、每次排便时间、大便形状及排便困难程度等临床症状积分、生活质量及疼痛评分等情况。结果：观察组在缩短患者首次排便时间、排便间隔时间

2、、每次排便时间及减轻患者排便困难程度等临床症状方面明显优于对照组（P<0.05）；且在提高生活质量及缓解疼痛程度方面亦优于对照组（P<0.05）。结论：麻子仁丸加减方可有效缓解癌痛患者应用阿片类药物引起的便秘，并可显著改善临床症状，提高患者生活质量。关键词麻子仁丸加减方；阿片类药物；便秘ObservationofTherapeuticEfficacyof"RevisedmazirenPill"intreatingintestinalconstipationcausingbyopiumtypesS

3、peciality:InternalMedicineofIntegratedTCMandWesternMedicineAuthor:YangmeiTutor:ProfessorLiXiurongAbstractObjective:Toobservetheclinicalefficacyof"RevisedmazirenPill"inthetreatmentofintestinalconstipationcausingbyopiumtypes.Methods:66subjectswithintes

4、tinalconstipationcausingbyopiumtypeswererandomlydividedintotwogroups,33patientsinthetreatmentgroupwereadministeredwith"RevisedmazirenPill",33inthecontrolgroupadministeredwithaetuloseliquo.Thentheclinicalsymptomscores,qualityoflife,bowelsintervaloftim

5、e,thetimeofeachdefecation,defecationstoolform,thedimensionsofthedifficultyforthedefecation,NRSandsoonwasevaluatedbeforetreatingandafter2weekstreating.Results:Treatmentgroupcanimproveclinicalsymptomandqualityoflifeaftertreating,andcanhelprelievePainin

6、tensityaftertreating.Treatmentgroupcanshortenbowelsintervaloftime,thefirsttimeofdefecationandthetimeofeachdefecation,canrelievethedifficultyforthedefecation,andontheeffectivenessTreatmentgroupbetterthancontrolgrope(P<0.05).Conclusion："RevisedmazirenP

7、ill"caneasesconstipationandpaineffectively,alsocanimprovequalityoflife.KeywordsRevisedmazirenPill,Opiumtypes,Intestinalconstipatio目录引言....................................................................................................................

8、...........1临床研究...............................................................................................................................21研究标准.....................................................................................................